Editorial: Adaptive designs: Appealing in development of therapeutics, and where do controversies lie?

Journal of Biopharmaceutical Statistics

Volumn 20, Issue 6, 2010, Pages 1083-1087

  Wang, Sue Jane ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTIVE DESIGN; CLINICAL RESEARCH; DRUG DESIGN; DRUG DEVELOPMENT; EDITORIAL; HUMAN; METHODOLOGY; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SYSTEMATIC ERROR;

CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; DRUG APPROVAL; GUIDELINES AS TOPIC; HUMANS; MODELS, STATISTICAL; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; TREATMENT OUTCOME; UNITED STATES;

EID: 78249276194     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543406.2010.514461     Document Type: Editorial

References (25)

1. Armitage, P., McPherson, K., Rowe, B. C. (1969). Repeated significance tests on accumulating data. Journal of the Royal Statistical Society Series A 132:235-244.
2. Bauer, P. (1989). Multistage testing with adaptive designs (with discussion). Biometrie und Informatik in Medizin and Biologie 20:130-148.
3. Bauer, P., Kohne, K. (1994). Evaluation of experiments with adaptive interim analysis. Biometrics 50:1029-1041.
4. Brannath, W., Burger, H. U., Glim, E., Stallard, N., Vandemeulebroecke, M., Wassmer, G. (2010). Comments on the draft guidance on "adaptive design clinical trials for drugs and biologics" of the U. S. Food and Drug Administration. Journal of Biopharmaceutical Statistics 20 (6):1125-1131.
5. Burman, C. F., Sonnesson, C. (2006). Are flexible designs sound? Biometrics 62:664-683.
6. Cheng, B., Chow, S. C. (2010). On the flexibility of adaptive designs and criteria for choosing a good one-A discussion of FDA draft guidance. Journal of Biopharmaceutical Statistics 20 (6):1171-1177.
7. Chuang-Stein, C., Beltangady, M. (2010). FDA draft guidance on adaptive design clinical trials: Pfizer's perspective. Journal of Biopharmaceutical Statistics 20 (6):1143-1149.
8. Cook, T., DeMets, D. L. (2010). Review of draft FDA adaptive design guidance. Journal of Biopharmaceutical Statistics 20 (6):1132-1142.
9. Ellenberg, S. S., Geller, N., Simon, R., Yusuf, S., eds. (1993). Proceedings of "Practical Issues in data monitoring of clinical trials", Bethesda, Maryland, USA, January 27-28, 1992. Statistics in Medicine 12:415-646.
10. Emerson, S. S., Fleming, T. R. (2010). Adaptive methods: Telling "the rest of the story." Journal of Biopharmaceutical Statistics 20 (6):1150-1165.
11. Hung, H. M. J., Wang, S. J., O'Neill, R. T. (2010). Flexible design clinical trial methodology in regulatory applications. Statistics in Medicine (www.interscience.wiley.com) doi: 10.1002/sim.4021.
12. Jennison, C., Turnbull, B. W. (2003). Mid-course sample size modification in clinical trials. Statistics in Medicine 22:971-993.
13. Müller, H.-H., Schäfer, H. (2004). A general statistical principle for changing a design any time during the course of a trial. Statistics in Medicine 23:2497-2508.
14. Shih, W. J., Gould, A. L. (1990). Interim Analysis for Sample Size Reestimation Without Unblinding Treatment Group Identification in Double-Blind Clinical Trials. Abstract no. 27, Society for Clinical Trials Eleventh Annual Meeting, Toronto, Ontario, Canada, 6-9 May.
15. Stein, C. (1945). A two-sample test for a linear hypothesis whose power is independent of the variance. Annals of Mathematical Statistics 16:243-258.
16. Tsiatis, A. A., Mehta, C. R. (2003). On the inefficiency of the adaptive design for monitoring clinical trials. Biometrika 90:367-378.
17. U. S. Food and Drug Administration. (2002). Code of Federal Regulation, 21CFR314.126. Food and Drug Administration, Health Human Services. Available at http://edocket.access.gpo.gov/cfr-2002/aprqtr/21cfr314.126.htm
18. U. S. Food and Drug Administration. (2010). Draft Guidance for Industry on Adaptive Design Clinical Trials for Drugs and Biologics. Released on February 25, 2010, for public comments. www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatory-Information/Guidances/UCM201790.pdf
19. Wang, S. J. (2010). Perspectives on the use of adaptive designs in clinical trials. Part I. Statistical considerations and issues. Journal of Biopharmaceutical Statistics 20 (6):1090-1097.
20. Wang, S. J., Hung, H. M. J., O'Neill, R. T. (2010a). Impacts of type I error rate with inappropriate use of learn for confirm in adaptive designs. Biometrical Journal Special Issue (accepted for publication).
21. Wang, S. J., Hung, H. M. J., O'Neill, R. T. (2010b). Adaptive design clinical trials in CNS drug development. European Neuropsychopharmacology Journal. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20933373 (last accessed October 19, 2010).
22. Wei, L. J., Durham, S. (1978). The randomized play-the-winner rule in medical trials. Journal of American Statistical Association 73:840-843.
23. Wittes, J. (2010). Comments on the FDA draft guidance on adaptive designs. Journal of Biopharmaceutical Statistics 20 (6):1166-1170.
24. Wittes, J., Brittan, E. (1990). The role of internal pilot studies in increasing the efficiency of clinical trials. Statistics in Medicine 9:65-72.
25. Zelen, M. (1969). Play the winner rule and the controlled clinical trials. Journal of American Statistical Association 64:131-146.